Is duloxetine indicated for the treatment of generalized anxiety disorder and other anxiety disorders?

Is Duloxetine Indicated for Anxiety?

Yes, duloxetine is FDA-approved for the treatment of generalized anxiety disorder (GAD) in adults and pediatric patients 7 years of age and older. 1

FDA-Approved Indications

Duloxetine delayed-release capsules are specifically indicated for:

• Generalized anxiety disorder in adults and pediatric patients ≥7 years of age 1
• Major depressive disorder in adults 1
• Diabetic peripheral neuropathic pain in adults 1
• Fibromyalgia in adults 1
• Chronic musculoskeletal pain in adults 1

Efficacy in Generalized Anxiety Disorder

Duloxetine 60-120 mg once daily demonstrates significant efficacy in treating GAD compared to placebo. 2

Adult Patients

• In four randomized, double-blind, placebo-controlled phase III trials, duloxetine 60-120 mg once daily for 9-10 weeks showed significantly greater improvement in Hamilton Anxiety Rating Scale (HAM-A) total scores compared to placebo 2
• Duloxetine improves patient role functioning, health-related quality of life, and overall well-being beyond just anxiety symptom reduction 2
• A meta-analysis of seven studies (n=2,674) demonstrated duloxetine's superiority with response rates (RR=1.48,95% CI 1.34-1.63) and remission rates (RR=1.60,95% CI 1.43-1.80) 3

Pediatric Patients

• Efficacy in pediatric patients aged 7-17 years was established in one 10-week placebo-controlled trial (GAD-6) with 272 patients 1
• Duloxetine demonstrated superiority over placebo as measured by the Pediatric Anxiety Rating Scale (PARS) for GAD severity 1
• Safety and effectiveness have not been established in pediatric patients under 7 years of age 1

Relapse Prevention

• In longer-term studies, duloxetine 60-120 mg once daily significantly delayed time to relapse in GAD responders compared to placebo over 26 weeks 2
• Significantly fewer duloxetine recipients relapsed during continuation treatment, and more achieved remission 2

Dosing and Administration

Start duloxetine at 60 mg once daily for GAD; doses up to 120 mg daily may be used based on response. 1

• Swallow capsules whole; do not chew, crush, or open 1
• May be taken with or without food, though administration with food may improve tolerability of the 60 mg dose 4
• Steady state is typically reached by day 3 of administration 2

Tolerability Profile

Duloxetine is generally well tolerated, with most adverse events being mild to moderate in severity. 2

Common Adverse Events

• Nausea, dry mouth, headache, constipation, dizziness, and fatigue are the most frequently reported 2
• Nausea is the most common reason for discontinuation 2
• The adverse event profile does not differ significantly with dose or treatment duration 2
• Administration with food may reduce the average number of adverse events per dose despite higher peak plasma concentrations 4

Critical Safety Warnings

• Black box warning: Increased risk of suicidal thoughts and behaviors in children, adolescents, and young adults, especially during initial treatment or dose changes 1
• Monitor all patients closely for clinical worsening and emergence of suicidal thoughts, particularly during the first few months 1
• Perform regular monitoring of weight and growth in pediatric patients 1

Contraindications and Drug Interactions

Do not use duloxetine with MAOIs or within 14 days of stopping an MAOI. 1

• Do not take an MAOI within 5 days of stopping duloxetine 1
• Risk of serotonin syndrome when combined with MAOIs, including linezolid or IV methylene blue 1
• Avoid concomitant use with potent CYP1A2 inhibitors 2
• Use caution with drugs extensively metabolized by CYP2D6, particularly those with narrow therapeutic index 2

Other Anxiety Disorders

Duloxetine is NOT FDA-approved for anxiety disorders other than GAD. 1

• No large-scale studies support its use in panic disorder, social anxiety disorder, obsessive-compulsive disorder, or post-traumatic stress disorder 5
• Only case reports and preliminary data exist for these conditions 5, 6
• The Japanese guidelines for social anxiety disorder recommend SSRIs (fluvoxamine, paroxetine, escitalopram) as first-line pharmacotherapy, not SNRIs like duloxetine 7

Special Populations

Geriatric Patients

• No overall differences in safety or effectiveness observed between geriatric and younger adult patients in clinical trials 1
• Increasing age is associated with higher plasma duloxetine concentrations 8

Pregnancy and Lactation

• Duloxetine may harm the unborn baby; discuss risks with patients who are pregnant or planning pregnancy 1
• Duloxetine passes into breast milk; monitor infants for sedation, poor feeding, and poor weight gain 1
• Peak concentration in breast milk occurs at median of 3 hours after dose, with estimated daily infant dose <1% of maternal dose 1

Hepatic and Renal Impairment

• Use with caution in patients with liver or kidney problems 1

Clinical Positioning

Duloxetine represents an effective first-line treatment option for GAD alongside SSRIs and other SNRIs. 2, 9

• Current consensus guidelines identify duloxetine, escitalopram, pregabalin, quetiapine, and venlafaxine as particularly effective treatments for GAD 9
• Pooled data show duloxetine's efficacy is comparable in magnitude to venlafaxine extended-release 2
• As a dual-acting SNRI targeting both serotonin and norepinephrine systems, duloxetine offers a mechanistically distinct option from SSRIs 2, 5